Autopsy report · NCT00914888

Study Evaluating Tigecycline Versus Ceftriaxone In Complicated Intra-Abdominal Infections & Community Acquired Pneumonia

Cause of deathNo reason given Automatic label, confidence 0.9, unverified. How labels are made.

The sponsor gave no reason.

Life of this trial

Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status: Withdrawn
Phase: Phase 3
Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer
Sponsor type: Industry
Conditions: Community Acquired Bacterial Pneumonia; Complicated Intra-Abdominal Infection
Interventions: Tigecycline; Tigecycline; cIAI: Ceftriaxone with metronidazole, plus if applicable aminoglycoside; CAP: Ceftriaxone, plus if applicable oral clarithromycin
Participants: 0

Look deeper

The official registry record (the source of truth)
Record history: every change the sponsor made
Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.